Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ViiV Healthcare

- PMLiVE

GSK gets OK in US for diabetes drug albiglutide

Once-weekly Tanzeum will compete against Victoza and Byetta after FDA approval

- PMLiVE

GSK under investigation in Poland for ‘camouflaged bribes’

A regional manager and 11 doctors have been charged, according to a BBC report

- PMLiVE

Teva launches first generic of GSK’s Lovaza in US

Will have six months of marketing exclusivity for copy of cardiovascular drug

- PMLiVE

GSK terminates lung cancer vaccine trial

Unable to identify patients who may benefit from MAGE-A3 immunotherapy

- PMLiVE

GSK halts bid for Votrient maintenance use

Pulls European application for indication in advanced ovarian cancer

- PMLiVE

GSK invests in African research and manufacturing

Boosts R&D for non-communicable diseases

- PMLiVE

EMA clears GSK’s diabetes therapy Eperzan

Once-weekly GLP-1 therapy will line-up against Victoza and Byetta

- PMLiVE

GSK withdraws melanoma combo in EU

EMA says it needs more data to review Mekinist and Tafinlar

- PMLiVE

GSK’s cancer vaccine flunks another trial

MAGE-A3 fails to improve survival in lung cancer patients

- PMLiVE

GSK to hire doctors as product champions

Will use in-house personnel instead of external speakers to present information

- PMLiVE

GSK set to file severe asthma candidate by year-end

Mepolizumab reduces frequency of exacerbations in late-stage trial

- PMLiVE

Pfizer still number one – just

The PMLiVE Top Pharma List is updated with a ranking of the 25 biggest companies in the industry

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links